Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018479 · ClinicalTrials.gov registry record · NA
Effects of a Female Hormone Balance Supplement on Premenstrual Syndrome Symptoms
A NA study of Premenstrual Syndrome, sponsored by Vinabas Formulations SL.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07018479: Completed NA study of Premenstrual Syndrome, sponsored by Vinabas Formulations SL.
NCT07018479 is a NA study of Premenstrual Syndrome that has completed, run by Vinabas Formulations SL. The registered enrollment target is 38 participants, below the 129-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07018479, a NA study of Premenstrual Syndrome, has completed, sponsored by Vinabas Formulations SL.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This virtual single-group study evaluates the effects of the FemmeBalance supplement on symptoms of premenstrual syndrome (PMS) over four menstrual cycles. The study involves daily intake of the supplement, regular questionnaires, and skin photo submissions for dermatological grading.
Primary Outcome
Change in self-reported symptoms of premenstrual syndrome, including pelvic pain, mood swings, acne, hair loss, fluid retention, breast pain/tenderness, irritability, and episodes of crying or sadness, assessed using validated questionnaires (PSST and study-specific tools).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT FemmeBalance Supplement Group
Study Locations (1)
Nevada
- Citruslabs - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2025-01-20 |
| Phase | NA |
What the finished NCT07018479 record still lists
NCT07018479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 129-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Premenstrual Syndrome appearing as the primary indexed condition, and to 1 intervention - of which FemmeBalance Supplement Group is the first listed.
NCT07018479 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT07018479 about?
NCT07018479 is a clinical study titled "Effects of a Female Hormone Balance Supplement on Premenstrual Syndrome Symptoms". This virtual single-group study evaluates the effects of the FemmeBalance supplement on symptoms of premenstrual syndrome (PMS) over four menstrual cycles. The study involves daily intake of the supplement, regular questionnaires, and skin photo submissions for dermatological grading.
What is the current status of trial NCT07018479?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2024-07-30. Estimated completion is 2025-01-20.
What conditions does trial NCT07018479 study?
This clinical trial studies the following conditions: Premenstrual Syndrome.
What interventions are being tested in trial NCT07018479?
The interventions under investigation include: FemmeBalance Supplement Group (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07018479?
This trial is sponsored by Vinabas Formulations SL, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07018479 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premenstrual Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms
RECRUITING · NA
-
Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome
COMPLETED · NA
-
A Study to Evaluate the Effect of Funk It Cycle Bites on PMS
COMPLETED · NA
-
Identification and Validation of Epigenetic Biomarkers of PMDD
RECRUITING
-
Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
COMPLETED · Phase 1
-
An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI